Bulk Pharmaceutical API Sources for BEVYXXA

Bulk Pharmaceutical API Sources for BEVYXXA

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS005146070
BioChemPartner		BCP9000395
Finetech Industry Limited		FT-0663094
Molport		MolPort-009-682-948
AbaChemScene		CS-2481
MedChemexpress MCE		HY-10268
BOC Sciences		330942-05-7

BEVYXXA (Betrixaban) Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

This report details the current landscape of bulk active pharmaceutical ingredient (API) suppliers for BEVYXXA (betrixaban), a direct Factor Xa inhibitor used for venous thromboembolism (VTE) prophylaxis. It identifies key manufacturers, their reported capacities, regulatory filings, and potential sourcing risks.

What is BEVYXXA (Betrixaban)?

BEVYXXA, with the chemical name N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidamido)benzamido)-5-methoxybenzamide, is an oral anticoagulant. Its primary therapeutic indication is for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2017 [1].

API Manufacturing Landscape for Betrixaban

The manufacturing of betrixaban API involves complex multi-step organic synthesis. Key considerations for sourcing include the number of suppliers, their geographic distribution, regulatory compliance (e.g., Good Manufacturing Practices - GMP), and supply chain resilience.

Leading API Manufacturers

Data from regulatory filings and industry reports suggest a concentrated manufacturing base for betrixaban API.

• Porton Pharma Solutions: This is a significant contract development and manufacturing organization (CDMO) with a strong presence in API production. Porton has demonstrated capabilities in producing complex small molecules and is likely a key supplier or potential supplier for betrixaban. Their manufacturing sites are subject to FDA inspections and are registered with the agency.
• WuXi AppTec: Another major global CDMO, WuXi AppTec also possesses the synthetic chemistry expertise and manufacturing infrastructure to produce betrixaban API. Their facilities operate under strict GMP guidelines and are often audited by regulatory bodies.
• Other Potential Manufacturers: While specific public disclosures are limited, it is common for pharmaceutical supply chains to involve multiple regional manufacturers, especially for established drugs. Companies in India and China are frequent producers of generic APIs. Companies with strong expertise in heterocyclic chemistry and amidations are prime candidates for betrixaban API production.

Geographic Distribution of API Production

The majority of bulk API production for pharmaceuticals, including complex molecules like betrixaban, is concentrated in Asia, primarily China and India.

• China: Dominates global API manufacturing due to cost advantages, established infrastructure, and a large pool of skilled chemists and technicians. Numerous Chinese CDMOs are capable of producing betrixaban.
• India: Also a significant player in API manufacturing, known for its strong generic pharmaceutical sector and competitive pricing. Many Indian companies are FDA-inspected and produce APIs for regulated markets.

Regulatory Filings and Compliance

The regulatory status of API manufacturers is crucial for pharmaceutical companies seeking to secure a reliable supply chain.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the U.S. FDA. A DMF is a submission to the agency made on a voluntary basis by a drug manufacturer that contains detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. [2] These filings are confidential but are referenced by drug product applicants.
• FDA Inspections: Facilities producing betrixaban API for the U.S. market must comply with FDA GMP regulations. Regular inspections by the FDA ensure that manufacturing processes meet quality and safety standards. A history of successful FDA inspections is a key indicator of a reliable supplier.
• European Medicines Agency (EMA) Compliance: For supply to the European market, API manufacturers must comply with EMA guidelines and undergo inspections by EU member state authorities.

Supply Chain Considerations and Risks

Sourcing betrixaban API presents several considerations and potential risks that pharmaceutical companies and investors must evaluate.

Production Capacity and Lead Times

• Capacity: While specific figures for betrixaban API production capacity are proprietary, the overall capacity of major CDMOs is substantial. However, demand fluctuations, other drug manufacturing contracts, and geopolitical factors can impact the availability of dedicated capacity.
• Lead Times: The synthesis of betrixaban is a multi-step process. Typical lead times for custom API manufacturing can range from 3 to 9 months, depending on the complexity of the process, raw material availability, and the manufacturer's existing production schedule.

Raw Material Sourcing and Cost Volatility

The synthesis of betrixaban relies on several key starting materials and intermediates.

• Key Intermediates: The supply chain for critical intermediates can be a bottleneck. For example, substituted pyridines and benzoic acid derivatives are likely essential building blocks.
• Supplier Concentration: If a particular intermediate is sourced from a limited number of suppliers, it can create a single point of failure in the supply chain.
• Price Fluctuations: Raw material costs are subject to global market forces, including supply and demand, energy prices, and geopolitical events. Volatility in raw material prices can directly impact the cost of betrixaban API.

Intellectual Property and Patent Expiry

• Composition of Matter Patents: The primary patents protecting betrixaban's composition of matter have expired or are nearing expiry in major markets. For example, U.S. Patent No. 7,759,324, related to betrixaban, expired in 2026. [3] This opens opportunities for generic manufacturers.
• Process Patents: While composition of matter patents expire, manufacturers may still hold patents related to specific synthetic routes or polymorphic forms of the API. Generic manufacturers must ensure their production processes do not infringe on existing process patents.
• Impact on Pricing: Patent expiry typically leads to increased competition and downward pressure on API prices as more suppliers enter the market.

Quality Control and Batch-to-Batch Consistency

• Analytical Methods: Robust analytical methods are required to ensure the purity, potency, and impurity profile of betrixaban API meet stringent pharmacopoeial standards (e.g., USP, EP).
• Impurity Profiling: Identification and control of process-related impurities and degradation products are critical for patient safety and regulatory approval.
• Quality Agreements: Comprehensive quality agreements between the API manufacturer and the drug product manufacturer are essential to define responsibilities for quality control, change management, and issue resolution.

Geopolitical and Environmental Risks

• Geopolitical Instability: Reliance on manufacturers in specific regions can expose the supply chain to risks from trade disputes, export restrictions, or political instability.
• Environmental Regulations: Increasingly stringent environmental regulations in countries like China and India can impact API production, potentially leading to temporary shutdowns or increased compliance costs for manufacturers.

Key Takeaways

The sourcing of bulk betrixaban API is primarily driven by a few large CDMOs with significant manufacturing capacity, predominantly located in Asia. While the expiration of composition of matter patents presents opportunities for generic entry and increased competition, potential sourcing risks include raw material dependency, geopolitical factors, and the need for stringent quality control. Pharmaceutical companies must conduct thorough due diligence on potential API suppliers, focusing on their regulatory compliance, manufacturing robustness, and supply chain transparency.

Frequently Asked Questions

1. Which major CDMOs are known to manufacture betrixaban API? Porton Pharma Solutions and WuXi AppTec are identified as significant CDMOs with the capabilities for producing complex APIs like betrixaban.

2. What are the primary geographical regions for betrixaban API manufacturing? The majority of bulk API production for betrixaban is concentrated in China and India.

3. What is the typical lead time for betrixaban API manufacturing? Lead times for betrixaban API production can range from 3 to 9 months, depending on the manufacturer's schedule and process complexity.

4. How do patent expiries affect betrixaban API sourcing? Patent expiries for betrixaban's composition of matter increase competition by allowing generic manufacturers to enter the market, potentially leading to lower API prices and a broader supplier base.

5. What regulatory documents are essential for betrixaban API suppliers? Essential regulatory documents include Drug Master Files (DMFs) filed with agencies like the FDA and evidence of successful Good Manufacturing Practices (GMP) inspections by regulatory authorities.

Citations

[1] U.S. Food and Drug Administration. (2017, June 23). FDA approves first oral Factor Xa inhibitor for extended duration, to reduce risk of blood clots in hospitalized patients with acute medical illness. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-first-oral-factor-xa-inhibitor-extended-duration-reduce-risk-blood-clots-hospitalized

[2] U.S. Food and Drug Administration. (2019, April 23). Drug Master Files. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-master-files

[3] United States Patent and Trademark Office. (n.d.). U.S. Patent 7,759,324. Retrieved from USPTO Patent Full-Text and Image Database. (Specific retrieval requires patent number search).